Skip to main content
. 2016 Jul 1;7(31):49459–49469. doi: 10.18632/oncotarget.10372

Figure 6. Overall survival in CD1d proficient and deficient TCL1 mice.

Figure 6

(A) CLL development was monitored in CD1d+/+TCL1 (n = 47) and CD1d−/− TCL1 (n = 26) mice and overall survival was assessed for both cohorts. (B) Overall survival of wildtype recipient mice transplanted (Tx) with TCL1 and CD1d−/− TCL1 tumors (CD1d−/− TCL1 Tx n = 4 and TCL1 Tx n = 8). (C) Overall survival of wildtype recipient mice transplanted with TCL1 tumors shown in (B; TCL1 Tx). Mice were grouped in two cohorts based on CD1d expression in peripheral blood (TCL1 Tx CD1dhigh n = 4 and TCL1 Tx CD1dlow n = 4) and percent survival was calculated.